RNA干擾療法市場：商業機會、成長要素、產業趨勢分析及2026-2035年預測。

全球RNA干擾療法市場預計到 2025 年將達到 42 億美元，並有望以 18.5% 的複合年成長率成長，到 2035 年將達到 314 億美元。

隨著現代藥物研發格局的不斷變革， RNA干擾（RNAi）療法市場正經歷強勁成長。這項變革的驅動力包括遺傳科學的進步、日益加重的疾病負擔以及對精準醫療的日益重視。 RNAi療法因其能夠選擇性地惰性致病基因而備受關注，為複雜的遺傳性疾病和慢性疾病提供了標靶治療方案。罕見遺傳和代謝疾病的日益普遍進一步推動了對創新基因惰性療法的需求。分子生物學、RNA遞送系統和藥物設計的持續進步正在提高療效和臨床應用性。先進遞送平台的整合顯著提高了標靶準確性、穩定性和安全性，從而促進了RNAi療法在臨床實踐中的更廣泛應用。製藥公司正加大對RNA相關研究計畫的投入，以拓展RNAi療法在多個治療領域的應用。孤兒藥和精準醫療監管支援的加強也有助於縮短研發週期，增加商業化機會。所有這些因素共同支撐著全球RNA干擾療法市場整體的長期強勁成長潛力。

預計到2025年，遺傳性轉甲狀腺素類澱粉沉積症（hATTR）市場將佔據35.7%的市場佔有率，到2035年將達到109億美元。該細分市場持續保持主導地位，主要得益於診斷率的提高以及針對該疾病的RNAi療法的已通過核准應用。 hATTR是一種由轉甲狀腺素蛋白基因突變引起的遺傳性疾病，導致異常蛋白質的積累，進而影響多個器官，並隨著時間的進行性引發進行併發症。臨床認知的不斷提高和治療手段的廣泛應用，將繼續推動該細分市場的成長。

預計到2035年，皮下給藥市場將以18.6%的複合年成長率成長。與靜脈注射相比，皮下給藥途徑更為便捷，臨床監測要求更低，患者依從性更高，因此備受青睞。先進的偶聯技術的應用使得皮下注射能夠實現高效的標靶遞送，從而在提高治療效果的同時，降低全身暴露及其相關副作用。這些優勢進一步鞏固了皮下給藥在RNAi療法中的主導地位。

預計到2025年，北美RNA干擾療法市場將佔據72%的佔有率，這主要得益於積極的臨床應用、先進的醫療基礎設施以及有利於罕見疾病治療的法規結構。該地區受益於早期獲得已通過核准的RNAi藥物，以及成熟的生物技術生態系統，為持續的研究和商業化提供支援。對基因研究的持續投入和不斷擴大的臨床能力將進一步鞏固北美在全球市場的主導地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 遺傳性疾病盛行率增加
    • RNA遞送技術的進步
    • 加大對基於RNAi的研究投入
    • 核准RNAi療法用於治療慢性病和罕見疾病
  • 產業潛在風險與挑戰
    • 有效遞送RNAi分子的挑戰
    • RNAi治療藥物研發高成本
  • 市場機遇
    • RNAi在神經病學和神經退化性疾病的應用
    • 針對遺傳疾病的個人化RNAi療法
• 成長潛力分析
• 技術展望
  • 目前技術
  • 新興技術
• 監理情勢
  • 北美洲
  • 歐洲
  • 亞太地區
• 波特的分析
• PESTLE分析
• 管道分析
• 人工智慧和生成式人工智慧對市場的影響
• 未來市場趨勢

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依適應症分類，2022-2035年

• 遺傳性轉甲狀腺素蛋白介導的類澱粉沉積症（hATTR）
• 轉甲狀腺素類澱粉沉積症伴隨心肌病（ATTR-CM）
• 急性肝紫質症（AHP）
• 原發性高草酸尿症第 1 型 (PH1)
• 高膽固醇症/血脂異常症
• 遺傳性乳糜微粒血症（FCS）

第6章 市場估計與預測：依給藥途徑分類，2022-2035年

• 皮下（SC）
• 靜脈注射（IV）

第7章 市場估計與預測：依最終用途分類，2022-2035年

• 醫院
• 專業治療中心
• 診所

第8章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 世界其他地區

第9章：公司簡介

• Commercial players
  • Alnylam Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Sanofi
  • Arrowhead Pharmaceuticals
• Emerging/pipeline players
  • Silence Therapeutics
  • Sirnaomics
  • Arbutus Biopharma
  • Benitec Biopharma
  • OliX Pharmaceuticals
  • Atalanta Therapeutics

The Global RNA Interference Therapeutics Market was valued at USD 4.2 billion in 2025 and is estimated to grow at a CAGR of 18.5% to reach USD 31.4 billion by 2035.

The RNA interference therapeutics market is witnessing strong expansion as advances in genetic science, growing disease burden, and increasing focus on precision medicine continue to reshape modern drug development. RNAi-based therapies are gaining momentum due to their ability to selectively silence disease-causing genes, offering targeted treatment options for complex genetic and chronic conditions. Rising prevalence of rare genetic disorders and metabolic diseases is further accelerating demand for innovative gene-silencing therapies. Continuous improvements in molecular biology, RNA delivery systems, and drug design are enhancing therapeutic performance and clinical applicability. The integration of advanced delivery platforms has significantly improved targeting accuracy, stability, and safety profiles, supporting broader clinical adoption. Pharmaceutical companies are increasingly investing in RNA-based research programs to expand treatment applications across multiple therapeutic areas. Growing regulatory support for orphan and precision medicines is also contributing to faster development timelines and commercialization opportunities. These factors collectively support strong long-term growth potential across the global RNA interference therapeutics market.

The hereditary transthyretin-mediated amyloidosis (hATTR) segment accounted for 35.7% share in 2025 and is expected to reach USD 10.9 billion by 2035. This segment continues to lead due to rising diagnostic rates and the availability of approved RNAi-based treatment options targeting the condition. hATTR is a genetic disorder caused by mutations in the transthyretin gene, resulting in abnormal protein buildup that affects multiple organs and leads to progressive complications over time. Increasing clinical recognition and treatment adoption continue to support segment growth.

The subcutaneous administration segment is projected to grow at a CAGR of 18.6% through 2035. This route of administration is widely preferred due to its convenience, reduced need for clinical supervision, and improved patient adherence compared to intravenous methods. The adoption of advanced conjugation technologies has enabled efficient targeted delivery through subcutaneous injection, improving therapeutic outcomes while reducing systemic exposure and associated side effects. These advantages continue to reinforce the dominance of this delivery approach in RNAi-based treatments.

North America RNA Interference Therapeutics Market accounted for 72% share in 2025, due to strong clinical adoption, advanced healthcare infrastructure, and favorable regulatory frameworks supporting rare disease therapies. The region benefits from early access to approved RNAi-based medicines and a well-established biotechnology ecosystem that supports ongoing research and commercialization. Continuous investment in genetic research and expanding clinical capabilities further strengthen North America's dominance in the global market.

Major companies operating in the global RNA interference therapeutics market include Novartis, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Sanofi, Novo Nordisk, Silence Therapeutics, Sirnaomics, Arbutus Biopharma, Benitec Biopharma, OliX Pharmaceuticals, and Atalanta Therapeutics. Companies operating in the RNA interference therapeutics market are strengthening their market position through continuous investment in RNA technology platforms, advanced delivery systems, and precision medicine development. Market participants are expanding clinical pipelines across multiple disease areas while improving molecular design strategies to enhance stability, efficacy, and targeting accuracy. Strategic collaborations with biotechnology firms, academic institutions, and research organizations are accelerating innovation and reducing development timelines. Companies are also focusing on scaling manufacturing capabilities to support commercial demand and ensure consistent product quality. In addition, increasing emphasis on targeted delivery technologies, regulatory approvals, and global expansion strategies is enabling firms to broaden their market reach, strengthen competitive positioning, and build long-term leadership in the RNA interference therapeutics market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Indication trends
  • 2.2.3 Route of administration trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of genetic disorders
    • 3.2.1.2 Advancements in RNA delivery technologies
    • 3.2.1.3 Rising investment in RNAi-based research
    • 3.2.1.4 Approval of RNAi therapeutics for chronic and rare diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Challenges in effective delivery of RNAi molecules
    • 3.2.2.2 High cost of RNAi therapeutics development
  • 3.2.3 Market opportunities
    • 3.2.3.1 RNAi applications in neurology and neurodegenerative diseases
    • 3.2.3.2 Personalized RNAi therapies for genetic diseases
• 3.3 Growth potential analysis
• 3.4 Technology landscape
  • 3.4.1 Current technology
  • 3.4.2 Emerging technologies
• 3.5 Regulatory landscape (Driven by primary research)
  • 3.5.1 North America
  • 3.5.2 Europe
  • 3.5.3 Asia Pacific
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Pipeline analysis (Driven by primary research)
• 3.9 Impact of AI and generative AI on the market (Driven by primary research)
• 3.10 Future market trends (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Hereditary transthyretin-mediated amyloidosis (hATTR)
• 5.3 Transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
• 5.4 Acute hepatic porphyria (AHP)
• 5.5 Primary hyperoxaluria type 1 (PH1)
• 5.6 Hypercholesterolemia / Dyslipidemia
• 5.7 Familial chylomicronemia syndrome (FCS)

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Subcutaneous (SC)
• 6.3 Intravenous (IV)

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty treatment centers
• 7.4 Clinics

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Rest of the world

Chapter 9 Company Profiles

• 9.1 Commercial players
  • 9.1.1 Alnylam Pharmaceuticals
  • 9.1.2 Novartis
  • 9.1.3 Novo Nordisk
  • 9.1.4 Sanofi
  • 9.1.5 Arrowhead Pharmaceuticals
• 9.2 Emerging/ pipeline players
  • 9.2.1 Silence Therapeutics
  • 9.2.2 Sirnaomics
  • 9.2.3 Arbutus Biopharma
  • 9.2.4 Benitec Biopharma
  • 9.2.5 OliX Pharmaceuticals
  • 9.2.6 Atalanta Therapeutics